Risk of new onset of immune-mediated diseases after SARS-CoV-2 infection: A systematic review and meta-analysis
Authors' conclusion
Our results support a higher risk of developing at least 11 immune-mediated diseases evaluated.
Study context
- Population
- Analytical observational studies reporting immune-mediated diseases after confirmed SARS-CoV-2 infection vs individuals without infection history8 studies
- Comparison
- Confirmed SARS-CoV-2 infection vs no infection history
- Outcome
- New onset of immune-mediated diseases (39 defined outcomes)
Methodological detailsrandom-effects model, Mantel-Haenszel method, diagnoses within first 30 days post-infection excluded
- Random-effects model
- Mantel-Haenszel method
- Diagnoses within first 30 days post-infection excluded
Pooled result
As reported in the abstract
Risk of new-onset immune-mediated diseases after SARS-CoV-2 infection (pooled RR, random-effects)
Lowest association in the range: SSc
2.31
95 % CI: 1.87–2.85
Highest association in the range: BD
3.71
95 % CI: 1.18–11.72
Original publication
Risk of new onset of immune-mediated diseases after SARS-CoV-2 infection: A systematic review and meta-analysis. Semin Arthritis Rheum. Published 5 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →